Michael Gelband’s Terns Pharmaceuticals TERN Stock Holding History

Michael Gelband’s Portfolio TERN Stock Details TERN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-80,245	Closed	-$4.23M	–	2059
2026 Q1	$4.23M	Sell	80,245 -295,428	-79%	-$12.1M	0.03%	492
2025 Q4	$15.2M	Buy	+375,673	New	+$8.68M	0.12%	151
2025 Q1	–	Sell	-10,816	Closed	-$60K	–	1977
2024 Q4	$60K	Sell	10,816 -1,637,315	-99%	-$11.1M	﹤0.01%	1421
2024 Q3	$13.7M	Buy	+1,648,131	New	+$13.6M	0.08%	187
2024 Q2	–	Sell	-54,722	Closed	-$359K	–	1976
2024 Q1	$359K	Buy	54,722 +7,182	+15%	+$46.9K	﹤0.01%	1219
2023 Q4	$309K	Buy	+47,540	New	+$251K	﹤0.01%	1173

Other funds holding TERN

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Michael Gelband's TERN Position: Q2 2026 in Review

Michael Gelband sold out of Terns Pharmaceuticals (TERN) in Q2 2026, closing a stake of 80,245 shares — an estimated $4.23M sold.

Michael Gelband first reported a position in TERN in Q4 2023 and held it in 6 quarters. The position peaked at $15.2M in Q4 2025. 1 fund tracked by Wall St. Rank holds TERN as of Q2 2026.

Michael Gelband reported no remaining Terns Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
Michael Gelband sold 80,245 Terns Pharmaceuticals shares in Q2 2026, an estimated $4.23M.
Michael Gelband first reported a position in Terns Pharmaceuticals in Q4 2023 and held it in 6 quarters.
Michael Gelband's Terns Pharmaceuticals position peaked at $15.2M in Q4 2025.
1 fund tracked by Wall St. Rank held Terns Pharmaceuticals as of Q2 2026.

Based on ExodusPoint Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.